⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
SNDX
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
globenewswire.com
SNDX
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
SNDX
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
globenewswire.com
SNDX
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
globenewswire.com
SNDX
Syndax Announces Participation in November Investor Conferences
globenewswire.com
SNDX